The spasticity-related quality of life 6-dimensions instrument in upper-limb spasticity: Part II A first psychometric evaluation.


Journal

Journal of rehabilitation medicine
ISSN: 1651-2081
Titre abrégé: J Rehabil Med
Pays: Sweden
ID NLM: 101088169

Informations de publication

Date de publication:
03 Jan 2022
Historique:
received: 02 11 2021
pubmed: 3 11 2021
medline: 5 1 2022
entrez: 2 11 2021
Statut: epublish

Résumé

Psychometric evaluation of the Spasticity-related Quality of Life 6-Dimensions instrument (SQoL-6D). A clinimetric evaluation conducted in a multicentre, prospective, longitudinal cohort study at 8 UK sites. Adult patients (n=104) undergoing focal treatment of upper-limb spasticity. The SQoL-6D was administered in the clinic at enrolment and at 8 weeks, then 1-4 days later at home to assess test-retest reliability. The SQoL-6D demonstrated adequate construct validity and unidimensionality of the scale, allowing the calculation of a Total score. Cronbach's alpha (0.74) supported the internal consistency reliability, while the intraclass correlation coefficient supported test-retest reliability (0.82). Correlation coefficients with established instruments supported convergent validity, while significant differences between known-groups (of differing clinical severity) in SQoL-6D Total score confirmed its sensitivity to both cross-sectional and longitudinal differences. The SQoL-6D is a promising new measure to assess health status for patients with upper-limb spasticity of any aetiology. Further investigation and exploration of the allocation of weights to convert the SQoL-6D to a health-related quality of life utility index, are required.

Identifiants

pubmed: 34726764
doi: 10.2340/jrm.v53.688
pmc: PMC8862650
doi:

Types de publication

Journal Article Multicenter Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

jrm00243

Références

JAMA. 1995 Jan 4;273(1):59-65
pubmed: 7996652
Phys Ther. 1987 Feb;67(2):206-7
pubmed: 3809245
J Chiropr Med. 2016 Jun;15(2):155-63
pubmed: 27330520
Pharmacoeconomics. 2015 Nov;33(11):1137-54
pubmed: 26040242
Health Serv Res. 1972 Summer;7(2):118-33
pubmed: 5044699
Health Qual Life Outcomes. 2003 Oct 16;1:54
pubmed: 14613568
Disabil Rehabil. 2017 Jul;39(14):1428-1434
pubmed: 27385274
J Clin Epidemiol. 2003 Jan;56(1):52-60
pubmed: 12589870
Disabil Rehabil. 2013 Aug;35(18):1513-8
pubmed: 23294435
Health Econ. 2018 Jan;27(1):7-22
pubmed: 28833869
Saudi J Anaesth. 2013 Oct;7(4):453-60
pubmed: 24348300
Hand Clin. 2018 Nov;34(4):437-443
pubmed: 30286958
J Clin Epidemiol. 2007 Jan;60(1):34-42
pubmed: 17161752
J Rehabil Med. 2009 Jun;41(7):536-44
pubmed: 19543664
Disabil Rehabil. 2014;36(1):23-31
pubmed: 23721497
J Health Econ. 2002 Mar;21(2):271-92
pubmed: 11939242
Health Econ. 2005 Jan;14(1):39-53
pubmed: 15386674
Arch Phys Med Rehabil. 2004 Jul;85(7):1063-9
pubmed: 15241751
Disabil Rehabil. 2005 Jan 7-21;27(1-2):2-6
pubmed: 15799140
BMJ Open. 2013 Jun 20;3(6):
pubmed: 23794582

Auteurs

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH